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The SWI3-related gene product (SRG3), a component of the mouse SWI/SNF complex, has been suggested
to have an alternative function. Here, we demonstrate that in the prostate transactivation of the androgen
receptor (AR) is modulated by SRG3 in multiple ways. The expression of SRG3, which is developmentally
regulated in the prostate, is induced by androgen through AR. SRG3 in turn enhances the transactivation of
AR, providing a positive feedback regulatory loop. The SRG3 coactivation of AR transactivation is achieved
through the recruitment of coactivator SRC-1, the protein level of which is upregulated by SRG3, providing
another pathway of positive regulation. Interestingly, SRG3 coactivation of AR transactivation is fully func-
tional in BRG1/BRM-deficient C33A cells and the AR/SRG3/SRC-1 complex formed in vivo contains neither
BRG1 nor BRM protein, suggesting the possibility of an SRG3 function independent of the SWI/SNF complex.
Importantly, the AR/SRG3/SRC-1 complex occupies androgen response elements on the endogenous SRG3 and
PSA promoter in an androgen-dependent manner in mouse prostate and LNCaP cells, respectively, inducing
gene expression. These results suggest that the multiple positive regulatory mechanisms of AR transactivation
by SRG3 may be important for the rapid proliferation of prostate cells during prostate development and
regeneration.
Androgens are important in prostate development as well as
in male sexual differentiation (13, 18). In the prostate, andro-
gens promote mitosis and differentiation of ductal epithelium
and furthermore appear to inhibit apoptosis of the differenti-
ated cells (25). Within 2 days of androgen ablation, the pros-
tate undergoes cell death, expressing apoptotic marker genes
such as TRPM-2 (10). Androgen withdrawal thus causes the
prostate to regress, while subsequent androgen injection allows
the prostate to regenerate (8, 16). However, the mechanisms
underlying the androgen-regulated regression and regenera-
tion of the prostate as well as development of the normal
prostate are not as yet understood.
Androgens act through the androgen receptor (AR), which
is a member of the nuclear receptor superfamily. The structure
of AR is similar to that of other nuclear receptors, having three
separate functional domains, a variable N-terminal activation
domain (AF-1), a central DNA-binding domain (DBD), and a
C-terminal ligand-binding domain (LBD) (44). Upon ligand
binding, the AR undergoes conformational changes that facil-
itate the formation of AR dimers in complex with specific
DNA sequences, called androgen response elements (AREs),
to enhance the transcription of target genes (33, 51). Tran-
scriptional activation of nuclear receptors, including AR, ap-
pears to involve interactions with coactivator molecules and
chromatin remodeling complexes so as to increase the tran-
scription rate of their target genes (9, 22, 37, 52). Coactivators
potentiate ligand-dependent transactivation of the receptor by
diverse modes of action, including direct interactions with
basal transcription factors and covalent modification of his-
tones and other proteins (2, 24, 40, 43). Chromatin-remodeling
complexes enhance the accessibility of nucleosomal DNA to
transcription factors (11, 32, 45) by generating a “remodeled”
state of chromatin.
SWI/SNF, a chromatin-remodeling complex, is required for
the regulation of transcriptional processes associated with de-
velopment, cellular differentiation, and proliferation (6, 26,
42). SWI/SNF is a 2-MDa multisubunit assembly that is highly
conserved in eukaryotes. Mammalian SWI/SNF complexes
contain one of two core ATPase subunits, BRM or BRG1, and
further diverge in the composition of their subunits, containing
another 7 to 14 BRG1- or BRM-associated factors (BAFs)
(47). The direct recruitment of chromatin-remodeling enzymes
by nuclear hormone receptors for attainment of full function
has been described for AR, glucocorticoid receptor, estrogen
receptor, and retinoid receptors (14, 15, 17, 36, 38, 46).
The SWI3-related gene product (SRG3), a mouse homo-
logue of yeast SWI3 and human BAF155, was initially isolated
as a gene highly expressed in the thymus, testis, and brain (26).
It has been shown to be a core component of mouse SWI/SNF
(26). In the thymus, SRG3 has been implicated in the glucocor-
ticoid sensitivity of T cells, associating with the glucocorticoid
receptor. Peripheral T cells of transgenic mice overexpressing
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SRG3 become more sensitive to glucocorticoid-induced apo-
ptosis (20), and downregulation of SRG3 expression by Notch1
allows developing thymocytes to be resistant to glucocorticoid-
induced apoptosis (7).
In this study, to understand the functional role of SRG3 in
the androgen regulation of prostate development, we investi-
gated its expression, gene regulation, and interaction with AR
in the prostate. Here, we show that SRG3, the expression of
which is upregulated by androgen through AR in the prostate,
enhances the transcriptional activity of AR, providing a posi-
tive feedback regulatory loop. Furthermore, SRG3 overexpres-
sion elevates the protein level of SRC-1, which is recruited by
SRG3 bound to AR, resulting in further enhancement of AR
transactivation. Thus, SRG3 may play an important role in the
rapid proliferation of cells during prostate development and
regeneration by amplifying AR function in multiple different
ways.
MATERIALS AND METHODS
Animals. Sprague Dawley (SD) rats were purchased from a commercial sup-
plier (Daehan Laboratories, Korea). Transgenic mice overexpressing SRG3 were
generated by microinjecting a DNA fragment of the chicken -actin promoter/
SRG3 open reading frame, which was cut out from the pCAGGSBS/mycSRG3
construct, into fertilized mouse eggs as previously described (20). Animals were
kept in a cage with water and chow available and maintained under controlled
conditions (12-h light and dark photoperiods, 50% humidity, 22°C). The ethical
treatment of animals in this study was carried out according to National Insti-
tutes of Health standards.
Plasmids. The mammalian expression vectors of pcDNA3-SRC-1, -p300,
-ARA70 and –mouse AR were previously described (34). The pARE2-TATA-
Luc and PSA-Luc reporter plasmids were previously described (27). Glutathione
S-transferase (GST)-mycSRG3, pcDNA3-mycSRG3, and LexA-mycSRG3 were
generated by cloning full-length mycSRG3 from the pCAGGSBS/mycSRG3
expression construct into pGEX4T-3, pcDNA3, and LexA202 vectors, respec-
tively. The SRG3-Luc reporter plasmid was constructed by cloning an SRG
promoter region (1200 to 3, 1 being the A base in the translation initiation
codon) into vector pGL3basic (Promega). SRG3 promoter deletion mutants
were constructed by self-ligation after digesting SRG3-Luc with Acc65I and BclI
(691 to 3), KpnI and ApaI (315 to 3), or Acc65I and XhoI (134 to 3).
Two other deletion mutants of SRG3 promoter were generated by PCR ampli-
fication using two primer sets: forward, 5-GTTCCGAGAGACCAGAGG-3,
and reverse, 5-GAGTTTTCACTGCATACGACG-3 for the277 to3 region
and forward, 5-ATGCGTACGCCCGCTCTC-3, and reverse, 5-GAGTTTTC
ACTGCATACGACG-3, for the 210 to 3 region.
The human BRG1 and BRM expression vectors were kind gifts from J. W. Lee
(Baylor College of Medicine) (29, 39). The GST-fused SRG3 deletion mutants
were constructed by cloning EcoRI-ScaI, ScaI-NotI, MfeI-HincII, and HincII-
XbaI fragments into either pGEX4T-3 or pGEX4T-2. pBluescript-mutSRG3
was generated by cloning a region spanning the Myb-like region and leucine
zipper motif (26), which is amplified by PCR using primer set forward, 5-TTG
CAGAACTTTGGTCTTCG-3, and reverse, 5-CTGTCTCTGTTGTTCTAGA
G-3. Hemagglutinin (HA)-mutSRG3-1 was constructed by cloning the EcoRI-
XbaI fragment of pBluescript-mutSRG3 into the pcDNA3HA vector.
mutSRG3-2 was constructed by self-ligation of pcDNA3-mycSRG3 partially di-
gested with XmnI. The B42-AR deletion mutants were generated by cloning the
regions spanning Tau, DBD/hinge, and LBD of mouse AR into vector B42
digested with EcoRI and XhoI restriction enzymes.
The SRG3-siRNA construct was generated by cloning annealed short inter-
fering DNA (siDNA) oligomers sense, 5-CGTGACAGAACAGACCAATTTC
AAGAGAATTGGTCTGTTCTGTCACGTTTTTT-3, and antisense, 5-AATT
AAAAAACGTGACAGAACAGACCAATTCTCTTGAAATTGGTCTGTTC
TGTCACGGGCC-3, into the pSilencer 1.0-U6 vector (Ambion, Inc.) digested
with ApaI and EcoRI enzymes. The BAF57 expression construct (pSG5-flag-
BAF57,4) and BAF47 siRNA construct (pREP4-PUR/u6-BAF47,12) were
kindly provided by M. G. Parker (Imperial College Faculty of Medicine, United
Kingdom) and K. Zhao (National Institutes of Health, Bethesda, Md.), respec-
tively. Two SRC-1 siRNAs were utilized, siRNA 1a (5-AACACGACGAAAU
AGCCAUAC-3) and 1b (5-AAGUGAUGACUCGUGGCACUG-3) (35). A
scrambled siRNA (5-AACCCGAAAGAUAACCGAUAC-3) was used as a
control for nonspecific gene disruption.
Transient transfection assays. The Cos-7, HeLa, L929, and C33A cell lines
were maintained in Dulbecco’s modified Eagle’s medium (DMEM) (Life Tech-
nologies, Inc.) supplemented with 10% fetal bovine serum. The LNCaP cell line
was purchased from the American Type Culture Collection (ATCC CRL-1740)
and maintained in RPMI 1640 (Life Technologies, Inc.) supplemented with
L-glutamine and 10% fetal bovine serum. Cells were plated in 24-well plates and
transfected with the indicated amount of expression plasmids, a reporter plas-
mid, and the control lacZ expression plasmid pCMV (Clontech) by using
Effectene reagent (QIAGEN, Germany) according to the manufacturer’s in-
structions. Total amounts of expression vectors were kept constant by adding
appropriate amounts of pcDNA3. Cells were treated with 10 nM dihydrotestos-
terone (DHT) for 24 h beginning 24 h following transfection. Luciferase and
-galactosidase activities were assayed as described previously (21). The levels of
luciferase activity were normalized to lacZ expression.
Northern blot analysis. Adult male Sprague-Dawley rats (75 to 80 days old)
were injected intraperitoneally with ethane dimethanesulfonate (EDS, 75 mg/kg
body weight) in dimethyl sulfoxide-water (1:3, vol/vol). Four days later, the
animals received an injection of 0.1 ml of 25 mg testosterone esters (Sustanon,
Organon Korea Ltd., Seoul, Korea) for the indicated time periods. Ventral
prostates were then collected and total RNAs were prepared using Tri reagent
(Molecular Research Center Inc.). Twenty micrograms of total RNA was sepa-
rated on a 1.2% denaturing agarose gel, transferred onto Zeta-probe nylon
membrane (Bio-Rad), and immobilized by UV cross-linking. The membrane was
hybridized with random-primed, 32P-labeled mouse SRG3, human BRG1, and
human BRM cDNA probes as described previously (21). The membrane was
reprobed for glyceraldehyde-3-phosphate dehydrogenase as a loading control.
Real-time RT-PCR. Total RNAs were obtained from the prostates of 28-day-
old nontransgenic and transgenic mice overexpressing SRG3 and LNCaP cells
transfected with pcDNA3-mycSRG3 or pcDNA3 empty vector. Quantitative
reverse transcription (RT)-PCR was performed with a real-time PCR machine
(Corbett Research, Sydney, Australia) and QuantiTect SYBR Green RT-PCR
(QIAGEN) according to the manufacturer’s procedure. PCRs were carried out
with the mouse SRC-1 primer set (forward primer, 5-TGAATCCAATGATG
GGCCAG-3, and reverse primer, 5-GATTCACTGTACACTGGACG-3) or
human PSA primer set (forward primer, 5-GGCCAGGTATTTCAGGTCAG-
3, and reverse primer, 5-CCACGATGGTGTCCTTGATC-3) and the -actin
primer set (forward primer, 5-GAGACCTTCAACACCCCAGCC-3, and re-
verse primer, 5-CCGTCAGGCAGCTCATAGCTC-3) as a quantitative con-
trol. Signals were analyzed with the Rotor Gene 2000 (RG-2000) software (Cor-
bett Research, Sydney, Australia).
Yeast two-hybrid assay. Plasmids encoding LexA fusions and B42 fusions were
cotransformed into Saccharomyces cerevisiae EGY48 containing the lacZ re-
porter plasmid. The transformants were grown in inducing medium and pro-
cessed for liquid  -galactosidase assays as described previously (21).
GST pull-down assay. GST, GST-AR domain mutant, and GST-SRG3 dele-
tion mutant fusion proteins were expressed in Escherichia coli BL21 cells and
isolated with glutathione-Sepharose 4B beads (Pharmacia Biotech AB, Sweden).
Immobilized GST fusion proteins were then incubated with [35S]methionine-
labeled SRG3, AR, or SRC-1 protein produced by in vitro translation using the
TNT coupled transcription-translation system (Promega). The binding reactions
were carried out in 250 l of GST binding buffer (20 mM Tris-HCl, pH 7.9, 100
mM NaCl, 10% glycerol, 0.05% NP-40, 5 mM MgCl2, 0.5 mM EDTA, 1 mM
dithiothreitol, and 1.5% bovine serum albumin) for 4 h at 4°C. The beads were
washed three times with 1 ml of GST binding buffer. Bound proteins were eluted
by adding 20 l of sodium dodecyl sulfate (SDS)-polyacrylamide gel electro-
phoresis (PAGE) sample buffer and analyzed by SDS-PAGE and autoradiogra-
phy.
Coimmunoprecipitation and Western blot assays. Coimmunoprecipitation as-
says were performed with untransfected L929 cells or Cos-7 cells which were
transfected either with 500 ng of AR (or HA-AR-DBDh), 750 ng of mycSRG3,
and 750 ng of SRC-1 expression plasmids or with 400 ng of AR, 400 ng of
HAmutSRG3, 400 ng of SRC-1, 400 ng of BRG1, and 400 ng of BRM expression
plasmids. Cells were treated with 10 nM DHT for 24 h following transfection and
harvested in radioimmunoprecipitation assay cell lysis buffer (50 mM Tris-HCl,
pH 7.5, 50 mM NaCl, 2.5 mM EGTA, 1% Triton X-100, 50 mM NaF, 10 mM
Na4P2O7, 10 mM Na3VO4, 1 g/ml aprotinin, 0.1 g/ml leupeptin, 1 g/ml
pepstatin, 0.1 mM phenylmethylsulfonyl fluoride, and 1 mM dithiothreitol).
Whole-cell lysate (400 g) was incubated with 2 g of anti-AR or anti-HA
antibody (Santa Cruz Biotechnology) for 4 h at 4°C and further incubated for
another 4 h after adding 20 l of protein A-agarose bead slurry (Invitrogen).
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Agarose beads were washed three times with radioimmunoprecipitation assay
buffer at 4°C, and bound proteins were separated by SDS-PAGE.
Total prostate proteins were prepared from 28-day-old nontransgenic and
transgenic male mice overexpressing SRG3 in tissue lysis buffer (50 mM Tris-
HCl, pH 8.0, 150 mM NaCl, 0.1% SDS, 0.1 mM phenylmethylsulfonyl fluoride,
1% NP-40, 0.5% sodium deoxycholate, and 1 g/ml aprotinin). HeLa cells were
cotransfected with AR, SRC-1, and -galactosidase expression plasmids (100 ng
each) with or without 100 ng of SRG3 expression plasmid. Transfected cells were
treated or not with 100 nM testosterone for 12 h after 24 h of transfection and
harvested in radioimmunoprecipitation assay buffer. Tissue or whole-cell lysates
were separated by SDS-PAGE. Proteins on the gels were transferred to a nitro-
cellulose membrane (Sigma), subjected to Western blot analysis with anti-SRG3
(26), anti-AR, anti-SRC-1, anti-p300, anti-ARA70, anti-HA, anti-BRG1, anti-
BRM, anti--galactosidase, and anti--actin antibodies (Santa Cruz Biotechnol-
ogy), and then detected with an ECL kit (Amersham Pharmacia).
Far-Western blot analysis. Whole L929 cell lysate prepared in RIPA buffer
was separated by SDS-PAGE, and proteins on the gel were transferred to
nitrocellulose membranes. The membrane was incubated with 1 g/ml of puri-
fied GST, GST-SRG3, or GST-ARDBDh fusion protein in Hyb75 buffer (50 mM
Tris-HCl, pH 8.0, 75 mM KCl, 0.1 mM EDTA, 2.5 mM MgCl2, 1 mM dithio-
threitol, and 0.05% NP-40) at 4°C overnight after blocking with 5% nonfat milk.
The membrane was then washed with Hyb75 buffer containing 1% nonfat milk
three times at room temperature and subjected to Western blot analysis with
anti-GST antibody.
Chromatin immunoprecipitation assay. The ventral prostates from 3-week-
old male mice injected with flutamide (100 mg/kg body weight) for 12 h were
dissected under the stereomicroscope, chopped, and cross-linked with 1% form-
aldehyde for 15 min at room temperature on a rotating platform. After 15 min,
the cross-linking reaction was stopped by the addition of glycine to a final
concentration of 0.125 M for 5 min at room temperature (50). LNCaP cells were
transfected with pcDNA3-SRG3 expression plasmid, treated or not with 10 nM
DHT for 6 h after 24 h of transfection, and cross-linked with 1% formaldehyde.
After incubating the samples with TSE I [100 mM Tris-HCl (pH 9.4) and 10 mM
dithiothreitol] for 20 min at 30°C, the cells were washed and processed for
chromatin immunoprecipitation (ChIP) assays as previously described (21). An-
ti-AR (Santa Cruz Biotechnology), anti-SRG3 (26), or anti-SRC-1 (Santa Cruz
Biotechnology) was used for immunoprecipitation.
Immunoprecipitated DNA and input-sheared DNA were subjected to PCR
using either mouse SRG3 primer pairs (sense, 5-CGGAAGCGTCATTCGTC
G-3, and antisense, 5-CATAGTCACCG TCCGTCG-3), which amplify a
317-bp region (314 to 3) spanning the putative androgen response element of
the mouse SRG3 promoter, or mouse PSA primer pairs (sense, 5-TGAGAAA
CCTGAGATTAGGA-3, and antisense, 5-ATCTCTCTCAGATC CAGGCT-
3), which amplify a 229-bp region (4271 to 4043) spanning the androgen
response element of the PSA promoter. As a negative control, PCRs were
performed using actin primer pairs (sense, 5-GAGACCTTCAACACCCCAG
CC-3, and antisense, 5-CCGTCAGGCAGCTCATAGCTC-3), which amplify
a 362-bp region spanning exon 4 of the -actin gene.
RESULTS
Androgen regulates the expression of SRG3 in rat prostate.
The proliferation rate of rat prostate increases from birth to 3
weeks of age, and thereafter it gradually decreases until it stops
by 8 weeks (49). To examine whether SRG3 expression coin-
cides with prostate proliferation, we performed Northern blot
analysis with rat prostates at different developmental stages
(Fig. 1A). The SRG3 expression was high in 2-week-old rat
prostate and gradually decreased until adulthood, suggesting a
role in prostate development. SRG3 expression in mouse pros-
tate also showed a similar pattern to that in rat prostate (data
not shown). On the other hand, the expression of BRG1 and
BRM, also core components of the SWI/SNF complex, exhib-
ited no significant changes during prostate development (Fig.
1A).
Because androgen is important for prostate proliferation, we
investigated whether SRG3 expression is regulated by andro-
gen in the prostate by treating rats with ethane dimethanesul-
fonate (EDS), a cytotoxic compound that specifically destroys
testicular Leydig cells and eventually leads to androgen depri-
vation in adult male rats (3, 27, 28). The expression of SRG3
in the prostate of EDS-treated rats was lowered compared to
that of vehicle-only-treated rats and reached a maximum ap-
proximately 6 h after androgen administration (Fig. 1B). Fur-
thermore, administration of the AR antagonist flutamide de-
creased the expression of SRG3 in the prostates of adult male
mice (Fig. 1C). These results suggest that SRG3 expression in
the prostate is controlled by androgen.
The gene regulation of SRG3 by androgen was further in-
vestigated by transient transfection analyses with 1.2 kb of the
SRG3 promoter. In LNCaP cells transfected with an SRG3
promoter-reporter construct, SRG3-Luc, luciferase activity
was increased approximately fourfold by treatment with 10 nM
DHT (Fig. 1D). Furthermore, in Cos-7 cells cotransfected with
an AR expression plasmid and SRG3-Luc, SRG3 promoter
activity was upregulated up to sixfold by AR in a dose-depen-
dent manner when the cells were treated with DHT (Fig. 1E).
Transient transfection analyses with serial deletion mutants
of the SRG3 promoter indicated that androgen response ele-
ments (AREs) might reside within the 67-bp region (277 to
211, 1 being the A base in the translation initiation codon)
of the SRG3 promoter (Fig. 1F), although sequence analysis of
the region did not show any good match with either canonical
or noncanonical AREs. The presence of putative AREs within
the SRG3 promoter region was further confirmed by chroma-
tin immunoprecipitation assay (ChIP) with the prostate of
3-week-old male mice. As shown in Fig. 1G, AR was recruited
onto the SRG3 promoter region (314 to 3) containing the
putative AREs, and recruitment was abolished by injection of
the AR antagonist flutamide. Together, these results suggest
that androgen regulates SRG3 expression at the transcrip-
tional level via AR.
SRG3 enhances the transactivation of AR. SWI/SNF chro-
matin remodeling complexes have been implicated in the mod-
ulation of transactivation of several nuclear receptors (14, 15,
17, 36, 38, 46). Because SRG3 is a core component of the
mouse SWI/SNF complex, we examined whether SRG3 mod-
ulates the transactivation of AR. In HeLa cells, coexpression of
SRG3 with AR increased the expression of a luciferase re-
porter gene in a dose-dependent manner when the cells were
treated with DHT (Fig. 2A). SRG3 also enhanced the trans-
activation of endogenous AR on a natural AR target pro-
moter, PSA, in LNCaP cells (Fig. 2B), and also on the SRG3
promoter (Fig. 2C), which had been shown to be an AR target
promoter (Fig. 1D to G). We then checked whether SRG3 is
necessary for the transactivation of AR in L929 cells, which
endogenously express AR and SRG3 (Fig. 6A) by silencing
SRG3 expression with siRNA. As shown in Fig. 2D, blocking
SRG3 expression inhibited the transactivation of AR, suggest-
ing the necessity of SRG3 for the full transactivation of AR in
L929 cells.
To examine whether SRG3 acting as an AR coactivator
depends on the SWI/SNF chromatin-remodeling complexes,
we tested its function in C33A cells, which are doubly deficient
in BRG1 and BRM (36, 38, 46). Unexpectedly, SRG3 en-
hanced AR transactivation in C33A cells as well as in other
cells, such as HeLa and LNCaP, in a dose-dependent manner
(Fig. 2E). Furthermore, the coexpression of either BRG1 or
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BRM with SRG3 failed to cooperatively activate AR transac-
tivation in C33A cells (Fig. 2F), while either BRG1 or BRM by
itself was able to increase the transactivation of AR, as recently
reported (36, 38, 46). Similarly, neither BAF57 nor BAF47,
other components of the SWI/SNF complex, cooperated with
SRG3 for the enhancement of AR transactivation, either when
BAF57 was overexpressed (Fig. 2G) or when BAF47 gene
expression was silenced with siRNA (Fig. 2H). Together, these
results suggest that SRG3 enhances the transactivation of AR
and probably does so in a manner independent of the SWI/
SNF complex.
SRG3 specifically cooperates with SRC-1 to modulate AR
transactivation. Because SRG3 itself has no histone acetyl-
transferase activity, we hypothesized that it cooperates with
FIG. 1. Expression of SRG3 is induced by androgen. (A) SRG3 expression during rat prostate development. Northern blot analysis of total
RNAs from prostate at different developmental stages was performed using 32P-labeled SRG3, BRG1, or BRM cDNA as a probe. The expression
of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control. (B) The transcript level of SRG3 is upregulated by
androgen in EDS-treated rat prostate. Rats were treated with EDS, and after 4 days the animals were supplemented with testosterone for the
indicated time. The expression of 18S rRNA was used as an internal control in Northern blot analysis. (C) SRG3 expression is downregulated in
mouse prostate by the administration of flutamide, an AR antagonist. Three-week-old male mice were injected or not with flutamide for 12 h. Total
prostate RNAs were subjected to Northern blot analysis. (D) The SRG3 promoter is induced by DHT in LNCaP cells expressing the endogenous
AR. The SRG3-Luc reporter (1,300 ng/well) containing the 1.2-kb fragment of the SRG3 promoter was transfected into LNCaP cells. (E) The
SRG3 promoter is induced by androgen in an AR dose-dependent manner. Cos-7 cells were cotransfected with 30 ng of SRG3-Luc and AR
expression plasmids (25, 50, and 150 ng). (F) Androgen target region within the SRG3 promoter was defined. Deletion mutants of the SRG3
promoter (30 ng) were cotransfected with 150 ng of AR expression plasmid into Cos-7 cells. Cells were treated or not with 10 nM DHT for 24 h.
(G) AR was recruited onto the SRG3 promoter region containing putative AREs. ChIP assays were performed with prostates dissected from
3-week-old male mice which had been injected or not with flutamide. The immunoprecipitates were analyzed by PCR using a pair of specific
primers spanning the SRG3 region containing putative AREs. A control PCR for nonspecific immunoprecipitation was performed using primers
specific to the -actin coding region.
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FIG. 2. SRG3 modulates AR transactivation. (A) SRG3 coexpression enhances AR transactivation. ARE2-TATA-Luc (50 ng) containing two
copies of androgen response elements was cotransfected with 5 ng of AR and increasing amounts of SRG3 expression plasmids (5, 10, 25, 50, and
150 ng) into HeLa cells. (B) SRG3 increases the transactivation of endogenous AR with the native androgen response PSA promoter. LNCaP cells
were cotransfected with 900 ng of PSA-Luc and 600 ng of SRG3 expression plasmids. (C) SRG3 enhances its own promoter activity by
up-regulating the transactivation of the endogenous AR. LNCaP cells were cotransfected with 900 ng of SRG3-Luc and increasing amounts of
SRG3 expression plasmids (200, 400, and 600 ng). (D) SRG3 is necessary for the transactivation of AR in L929 cells. L929 cells were cotransfected
with 55 ng of ARE2-TATA-Luc together with 250 or 500 ng of SRG3 siRNA expression plasmid. Decreased protein expression of the endogenous
SRG3 gene with transfection of 500 ng of SRG3 siRNA plasmid is shown at the bottom. (E) SRG3 activates AR transactivation in a
dose-dependent manner in C33A cells. C33A cells were cotransfected with 55 ng of ARE2-TATA-Luc together with 20 ng of AR and increasing
amounts of SRG3 expression plasmids (20, 40, and 100 ng). Increased protein expression of SRG3 and absence of induced expression of BRG1
and BRM are shown at the bottom. The SRG3 antibody used also recognizes the human BAF155 protein, so that a certain level of the signal
appeared in C33A cells transfected without SRG3. Western blot analysis with anti-human BAF155 antibody (Santa Cruz Biotechnology) gave a
similar result (data not shown). (F) SRG3 does not cooperate with either BRM or BRG-1 to enhance AR transactivation. ARE2-TATA-Luc (50
ng) was cotransfected with 20 ng of AR and a combination of the indicated expression plasmids (20 or 60 ng of SRG3 and 20 ng of BRG1 or BRM).
Expression of AR, BRM, and BRG1 proteins from the expression plasmids in C33A cells is shown at the bottom. (G) BAF57 does not affect the
SRG3-mediated enhancement of AR transactivation. HeLa cells were cotransfected with 55 ng of ARE2-TATA-Luc, 20 ng of AR, and 100 ng of
SRG3 expression plasmids together with 25 or 50 ng of BAF57 expression plasmid. (H) BAF47 does not affect the SRG3-mediated enhancement
of AR transactivation. HeLa cells transfected with 60 or 120 ng of the BAF47 siRNA construct or empty vector were selected in 1 g/ml of
puromycin for 2 days (12) and then cotransfected with 55 ng of ARE2-TATA-Luc, 20 ng of AR, and 100 ng of SRG3. Cells were treated or not
with 10 nM DHT for 24 h.
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histone acetyltransferase to activate AR transactivation. We
first tested SRC-1 and p300, which are known to act as AR
coactivators, along with ARA70. As shown in Fig. 3A and 3B,
the coexpression of SRG3 with SRC-1 cooperatively increased
the expression of the reporter directed by the SRG3 and PSA
promoters in LNCaP cells compared with controls expressing
only SRG3 or SRC-1. However, SRG3 coexpression affected
neither the p300 nor ARA70 coactivation of AR transactiva-
tion on either the SRG3 or PSA promoter. We observed the
same cooperative coactivation of AR transactivation by SRG3
and SRC-1 in C33A cells (Fig. 3C).
We then tested whether the recruitment of SRC-1 is neces-
FIG. 3. SRG3 cooperates specifically with SRC-1 to enhance AR transactivation. (A) SRC-1 but neither p300 nor ARA70 enhances the ability
of SRG3 to transactivate AR on its own promoter. LNCaP cells were cotransfected with 900 ng of SRG3-Luc and a combination of the indicated
expression plasmids (200 ng of SRG3 expression plasmid and 400 ng of SRC-1, p300, or ARA70 expression plasmid). (B) SRC-1 enhances the
ability of SRG3 to transactivate AR on the PSA promoter. LNCaP cells were cotransfected with 900 ng of PSA-Luc and a combination of the
indicated expression plasmids (200 ng of SRG3 expression plasmid and 400 ng of SRC-1, p300, or ARA70 expression plasmid). Expression levels
of SRC-1, p300, and ARA70 as well as SRG3 protein are shown at the bottom. (C) SRC-1 enhances the ability of SRG3 to transactivate AR in
C33A cells. ARE2-TATA-Luc (55 ng) was cotransfected with 20 ng of AR and a combination of the indicated expression plasmids (20 ng of SRG3
plus either 20 or 60 ng of SRC-1). (D) SRC-1 recruitment is necessary for SRG3 coactivator function. Cos-7 cells were transfected with 40 ng of
ARE2-TATA-Luc, 20 ng of AR, and 80 ng of SRG3 expression plasmids along with no siRNA, 100 nM each of both SRC-1 siRNA 1a and 1b,
or 200 nM of scrambled siRNA as a control. The cells were then treated or not with 10 nM DHT for 24 h. Decreased SRC-1 protein expression
in Cos-7 cells with transfection of both SRC-1 siRNA 1a and 1b is shown at the bottom. (E) AR receptor levels were little affected by coexpression
of SRG3, SRC-1, BRG1, or BRM. Cos-7 cells were transfected with 100 ng of AR and 100 ng of the indicated cofactor expression plasmid and
treated with 10 nM DHT for 24 h. Western blot analyses were performed with each of the corresponding anti-cofactor antibodies.
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sary for SRG3 to enhance AR transactivation by silencing the
endogenous SRC-1 expression with siRNA in Cos-7 cells. In
cells treated with SRC-1 siRNA but not with scrambled siRNA
as a control, the AR transactivation itself was significantly
impaired and SRG3 no longer enhanced the AR transactiva-
tion in the presence of androgen (Fig. 3D). Meanwhile, AR
receptor levels were little affected by coexpression of SRG3,
SRC-1, BRG1, or BRM in transient transfection experiments
(Fig. 3E). Together, these results suggest that SRG3 enhances
AR transactivation by specifically recruiting SRC-1.
SRG3 upregulates the SRC-1 protein level. Interactions be-
tween two coactivators or between a nuclear receptor and its
coactivator have been reported to increase the stability of one
of the participant proteins, resulting in an upregulation of the
protein level (1, 19, 31). Because SRG3 cooperated with
SRC-1 in the enhancement of AR transactivation, most likely
via physical association, we examined the effect of SRG3 on
the SRC-1 protein level in HeLa cells cotransfected with AR,
SRC-1, and the control -galactosidase expression plasmids
with or without the SRG3 expression vector.
As shown in Fig. 4A, the SRC-1 protein level was signifi-
cantly higher in cells with SRG3 coexpression than in cells
without it. Treatment with testosterone did not affect the level
of SRC-1 protein. In addition, SRG3 overexpression in L929
cells upregulated the level of endogenous SRC-1 protein, while
overexpression of an SRG3 mutant form (mutSRG3-2, Fig.
6D) that has its Myb-like region (MLR) deleted and is unable
to enhance the AR transactivation, did not (Fig. 4B). Further-
more, when SRG3 expression in the prostate of 2-week-old
male rats was upregulated by injecting DHT because SRG3
expression is androgen inducible (Fig. 1), the SRC-1 protein
level was elevated too (Fig. 4C).
We also investigated the SRG3 effect on the SRC-1 protein
level using transgenic mice overexpressing SRG3. As shown in
Fig. 4D, the overexpressed SRG3 upregulated the protein level
of SRC-1 but neither p300 nor ARA70 in the prostate. This
could be due to the increased stability of the SRC-1 protein or
the increased translational efficiency of its mRNA, because the
level of the SRC-1 mRNA exhibited no difference in the
SRG3-transgenic and nontransgenic mouse prostates (Fig.
4E).
SRG3 physically associates with AR and SRC-1 in vitro. To
verify that the functional interaction between SRG3 and AR
involves a physical association, we performed yeast two-hybrid
analyses using SRG3 fused to the LexA DNA binding domain
(LexA-SRG3) and AR domain mutants fused to the B42 acti-
FIG. 4. SRG3 upregulates the level of SRC-1 protein. (A) Coexpression of SRG3 upregulates the level of SRC-1 protein. AR, SRC-1, and the
control -galactosidase expression plasmids (100 ng each) were cotransfected with or without SRG3 expression vector into HeLa cells. The cells
were treated or not with 100 nM of testosterone (T). Western blot analyses were carried out with anti-SRC-1, anti-AR, and anti--galactosidase
antibodies. (B) SRG3 overexpression upregulates the level of endogenous SRC-1 protein. L929 cells were transfected with empty vector,
myc-SRG3, or myc-mutSRG3-2 expression plasmid in the presence of 10 nM DHT. Western blot analyses were carried out with anti-SRC-1,
anti-myc (SRG3), and anti--actin antibodies. (C) Up-regulation of SRG3 expression by DHT in rat prostate causes the elevation of SRC-1 protein
level. Two-week-old rats were injected with DHT at 3 mg/kg body weight for 24 h. (D) SRG3 overexpression causes the up-regulation of SRC-1
protein level. Prostate extracts were prepared from 4-week-old SRG3-transgenic and nontransgenic mice (four animals for each sample). Western
blot analyses were performed with anti-SRG3, anti-SRC-1, anti-p300, anti-ARA70, and anti--actin antibodies. (E) The mRNA level of SRC-1 was
not affected by SRG3 overexpression. Total RNAs were prepared from the prostates of 4-week-old SRG3-transgenic and nontransgenic mice.
Mouse SRC-1 transcripts were analyzed by real-time RT-PCR. -Actin was used as a quantitative control.
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vation domain (B42-AR domain mutants). As shown in Fig.
5A, LexA-SRG3 itself showed a low basal level of -galacto-
sidase activity, and so did B42-AR-Tau, B42-AR-DBDh, and
B42-AR-LBD alone. However, the presence of LexA-SRG3
with B42-AR-DBDh strongly induced -galactosidase activity,
while the presence of LexA-SRG3 with B42-AR-LBD very
weakly induced the expression of the reporter in the presence
of testosterone. These results indicate that SRG3 interacts
with AR and the DBDh region of AR is the major determinant
for this interaction.
Direct physical interaction between SRG3 and AR was then
assessed by glutathione S-transferase (GST) pull-down analy-
ses (Fig. 5B). [35S]methionine-labeled SRG3 produced by in
vitro translation was incubated with the GST fusion protein of
AR domain mutants, while [35S]methionine-labeled AR was
incubated with the GST fusion protein of SRG3 (full-length)
and its deletion mutants. SRG3 interacted with GST-AR-
DBDh but not with GST-AR-Tau or GST–AR-LBD. On the
other hand, AR interacted with the GST-SRG3 full-length and
C-terminal regions but not with the N-terminal region. Inter-
estingly, AR interacted with the region spanning a leucine
zipper motif of the C-terminal region (amino acid residues 722
to 942). These results suggest that SRG3 directly interacts with
AR and the DBDh of AR and the leucine zipper-containing
region of SRG3 are responsible for the interaction.
Because transient transfection analyses showed that SRG3
specifically cooperates with SRC-1 to enhance AR transacti-
vation (Fig. 3), the physical interaction between SRG3 and
SRC-1 was investigated by GST pull-down analysis (Fig. 5C).
SRC-1 interacted with GST-SRG3 full-length and C-terminal
regions but not with the N-terminal region. Furthermore,
SRC-1 interacted with the Myb-like region in its C-terminal
(amino acid residues 611 to 721), but not with the leucine
zipper-containing region. These results suggest that SRG3 di-
FIG. 5. SRG3 physically associates with AR and SRC-1 in vitro. (A) SRG3 interacts with AR through the DBDh region of AR. The interaction
between AR and SRG3 was scored by activation of the -galactosidase reporter in the yeast two-hybrid system. All values represent the mean 
standard error of the mean of at least three independent colonies. (B) The DBDh region of AR interacts directly with SRG3 through a region
spanning a leucine zipper motif (LZ) in the SRG3 C terminus. [35S]methionine-labeled SRG3 and AR were allowed to bind the GST fusion
proteins of AR domain mutants and SRG3 deletion mutants, respectively. Reactions were carried out with an equivalent amount of each protein
as determined by Coomassie blue staining (data not shown). Ten percent of the labeled protein used in the binding reaction was loaded as the
input. (C) SRG3 interacts directly with SRC-1 through its Myb-like region (MLR). [35S]methionine-labeled SRC-1 was allowed to bind the
GST-fused SRG3 and its deletion mutants. (D) SRG3 interacts directly with both AR and SRC-1, while AR interacts with SRG3. Far-Western
blot analyses were performed with L929 cell extracts. Nitrocellulose membranes containing proteins of the L929 cell extract were incubated with
purified GST, GST-AR-DBDh, or GST-SRG3 fusion protein following Western blot analysis with anti-GST antibody.
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rectly interacts with SRC-1 and has a region for SRC-1 binding
distinct from the region for AR binding.
Direct physical interactions between SRG3, AR, and SRC-1
were further confirmed by Far-Western blot analyses using
purified GST fusion proteins. Proteins in the extract of L929
cells which endogenously express SRG3, AR and SRC-1 (Fig.
6A) were separated by SDS-PAGE and transferred to a nitro-
cellulose membrane. The membrane was then incubated with
purified GST, GST-AR-DBDh, or GST-SRG3 fusion protein,
and the L929 cell proteins which interacted with each GST
fusion protein were detected with an anti-GST antibody. GST-
SRG3 protein bound SRC-1 and AR, while GST-AR-DBDh
protein bound SRG3 (Fig. 5D). These results indicate that
SRG3 interacts directly with both AR and SRC-1, while AR
interacts with SRG3.
SRG3 forms a complex with AR and SRC-1 in vivo and may
function as an AR coactivator in an SWI/SNF complex-inde-
pendent way. To determine whether AR protein forms a com-
plex with SRG3 and SRC-1 in vivo, coimmunoprecipitation
experiments were carried out using L929 cells which were
treated or not with DHT (Fig. 6A). L929 is a mouse fibroblast
cell line and endogenously expresses AR, SRG3, SRC-1,
BRG1, and BRM. Immunoprecipitation of whole-cell extracts
was performed using an anti-AR antibody. Western blot anal-
yses of the immunoprecipitated material revealed that SRG3
and SRC-1 endogenously associated with AR, but only when
the cells were treated with DHT. SRC-1 itself has been re-
ported to interact directly with AR through both the AF-1 and
LBD of AR (5). The recruitment of SRC-1 to AR through
SRG3 was confirmed by coimmunoprecipitation experiments
using an AR mutant containing only its DBDh region, which
can interact with SRG3 but not with SRC-1. SRC-1 was asso-
ciated with AR (DBDh) only in the presence of SRG3 (data
not shown).
Because the earlier results revealed that SRG3 functions as
an AR coactivator in the absence of BRG1 and BRM in C33A
cells (Fig. 2E and F), we investigated whether BRG1 or BRM
is associated with the endogenous AR/SRG3/SRC-1 complex
in L929 cells. Western blot analyses of the AR-immunopre-
cipitated material revealed that AR/SRG3/SRC-1 complex did
not contain either BRG1 or BRM (Fig. 6A), again suggesting
the possibility of SRG3 coactivator function in a manner that
is SWI/SNF complex independent.
To further address the findings that SRG3 coactivator func-
tion is independent of the chromatin-remodeling complex, we
generated an SRG3 deletion mutant (amino acid residues 611
FIG. 6. AR and SRG3 form a complex with SRC-1 in vivo and may function as an AR coactivator in a manner independent of the SWI/SNF
complex. (A) AR endogenously forms a complex with SRG3 and SRC-1 in the presence of androgen, and the complex does not contain BRG1
or BRM. L929 cells were treated or not with 10 nM DHT for 24 h. Coimmunoprecipitations were carried out with anti-AR antibody.
(B) mutSRG3-1 containing only the Myb-like region and leucine zipper domain is able to associate with AR and SRC-1 but not with BRG1 or
BRM in vivo. Cos-7 cells were cotransfected with HA-mutSRG3, AR, SRC-1, BRG1, and BRM expression plasmids. Coimmunoprecipitation
experiments were carried out with anti-HA (mutSRG3-1) antibody. Western blot analyses of immunoprecipitated materials were performed with
anti-AR or anti-HA, anti-SRG3, anti-SRC-1, anti-BRG1, and anti-BRM antibodies. Input Western blots are shown for the expression level of each
protein. (C) mutSRG3-1 is able to enhance AR transactivation. Fifty ng of ARE2-TATA-Luc reporter plasmid was cotransfected along with 5 ng
of AR and increasing amounts of mutSRG3-1 (20, 50, and 100 ng) into Cos-7 cells. Either 20 ng or 100 ng of SRC-1 expression plasmid was also
cotransfected as indicated. (D) mutSRG3-2, a mutant that is no longer able to bind SRC-1, is unable to enhance AR transactivation. Fifty ng of
ARE2-TATA-Luc reporter plasmid was cotransfected along with 5 ng of AR, 50 ng of either SRG3 or mutSRG3-2, and 50 ng of SRC-1 into Cos-7
cells. Cells were treated or not with 10 nM DHT for 24 h.
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to 942) containing only the Myb-like region for the interaction
with SRC-1 and the leucine zipper domain for the interaction
with AR (Fig. 5B and C). Coimmunoprecipitation experiments
were carried out using Cos-7 cells transfected with HA-tagged
SRG3 mutant, AR, SRC-1, BRG1, and BRM expression vec-
tors. Immunoprecipitation of whole-cell extracts was per-
formed with an anti-HA (mutSRG3-1) antibody. As expected,
the SRG3 mutant was able to associate with SRC-1 and AR
but not with BRG1 and BRM in vivo (Fig. 6B). Transient
transfection analyses with the SRG3 mutant revealed that the
mutant was able to enhance the transactivation of AR in a
dose-dependent manner (Fig. 6C), as did wild-type SRG3.
Furthermore, coexpression of SRC-1 with the SRG3 mutant
cooperatively increased the expression of the reporter. Mean-
while, a SRG3 mutant (deletion of amino acid residues 613 to
723, mutSRG3-2), which has its MLR region deleted and thus
is no longer able to bind SRC-1, was significantly unable to
enhance AR transactivation in the presence or absence of
SRC-1 overexpression (Fig. 6D). Together, these results fur-
ther support the view that the SRG3 coactivator function is
independent of the SWI/SNF complex.
AR, SRG3, and SRC-1 are recruited to AR target promoters
in response to androgen in vivo. To determine whether AR,
SRG3, and SRC-1 form a complex on AR target promoters in
vivo, we performed ChIP assays with prostates dissected from
male mice which were injected with flutamide or not (Fig. 7A).
In the absence of flutamide injection, AR, SRG3, and SRC-1
associated with the SRG3 promoter in the prostate, while
flutamide injection resulted in the failure of recruitment of
these factors to the SRG3 promoter. We also performed ChIP
assays with LNCaP cells transfected with an SRG3 expression
plasmid and then treated or not with DHT (Fig. 7B). Andro-
gen treatment induced AR, SRG3, and SRC-1 to associate
with the PSA promoter, while none of them was recruited to
the promoter in the absence of DHT treatment. Furthermore,
SRG3 overexpression in LNCaP cells upregulated androgen-
dependent transcription of the endogenous PSA gene (Fig.
7C). Together, these results suggest that in vivo the AR/SRG3/
SRC-1 complex occupies AREs on the SRG3 and PSA pro-
moters in an androgen-dependent manner, inducing gene ex-
pression.
DISCUSSION
In this study, it is demonstrated that SRG3 functions as an
AR coactivator, recruiting SRC-1 to AR target promoters such
as SRG3 and PSA. This SRG3 function is probably indepen-
dent of the BRG1/BRM-containing SWI/SNF complex be-
cause SRG3 works in BRG1/BRM-deficient C33A cells as well
as in other normal cells, the AR/SRG3/SRC-1 complex con-
tains neither the BRG1 nor BRM protein in vivo, and an
SRG3 mutant (mutSRG3-1) which is unable to associate with
BRG1 or BRM is able to enhance AR transactivation, as does
wild-type SRG3.
SRG3, known to be a mouse homologue of yeast SWI3,
Drosophila MOIRA, and human BAF155, is also a core com-
ponent of the SWI/SNF chromatin-remodeling complex (6, 26,
42). However, the expression pattern of SRG3 has been shown
to be basically similar to but somewhat different from that of
both BRG1 and BRM during mouse embryogenesis, which
suggests that some SRG3 proteins may not be components of
either the BRG1- or BRM-containing SWI/SNF complexes
and may have an alternative novel function(s) (30). In addition,
the expression of the SRG3 homologue BAF155 is different
from that of the major components of the SWI/SNF complex in
certain human cell lines (48). Furthermore, in this study, SRG3
was different in expression pattern from BRG1 and BRM
during rat prostate development and in the expression re-
sponse to androgen in rat prostate. These findings further
support the suggestion that SRG3 has an alternative function
in addition to being a subunit of the SWI/SNF complex.
Recently, SRG3 has been reported to associate with glu-
cocorticoid receptor to regulate glucocorticoid receptor trans-
activation in a thymoma cell line (20). However, it has not been
FIG. 7. AR, SRG3 and SRC-1 are recruited to AR target promot-
ers in response to androgen in vivo. (A) ChIP assays were performed
with prostates dissected from 3-week-old male mice that had been
injected or not with flutamide at 100 mg/kg body weight for 12 h.
(B) ChIP assays were performed with LNCaP cells transfected with
SRG3 expression plasmid and then treated or not with 10 nM DHT for
6 h. Anti-AR, anti-SRG3, and anti-SRC-1 antibodies were used for
immunoprecipitations. The immunoprecipitates were analyzed by
PCR using a pair of specific primers spanning the region containing the
AREs of the SRG3 promoter in mouse prostate and the PSA promoter
in LNCaP cells. A control PCR for nonspecific immunoprecipitation
was performed using primers specific to the -actin coding region.
(C) SRG3 overexpression elevates androgen-dependent transcription
of the endogenous PSA gene. LNCaP cells were transfected with
SRG3 expression plasmid or empty vector and then treated or not with
10 nM DHT for 24 h. PSA transcripts were analyzed by real-time
RT-PCR of total RNAs. -Actin was used for a quantitative control.
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made clear whether SRG3 interacts directly with glucocorti-
coid receptor or whether the modulation of glucocorticoid
receptor transactivation by SRG3 is BRM/BRG1 independent.
Meanwhile, the SWI/SNF chromatin-remodeling complex has
been reported to be needed for glucocorticoid receptor trans-
activation (17, 39, 41, 53), in which BAF60a and BAF57 but
not BRG1, BAF155, or BAF170 turn out to be direct links
between glucocorticoid receptor and the chromatin-remodel-
ing complex (23). BAF60a also interacts with progesterone
receptor b, estrogen receptor alpha, and farnesoid receptor. In
addition, BAF57 has been reported to be a direct link between
estrogen receptor and the SWI/SNF complex (4). Thus, this
report of SRG3 interaction with AR is the first evidence of a
direct interaction between SRG3 (BAF155) and the steroid
nuclear receptor. This may be further evidence for the SWI/
SNF complex-independent function of SRG3, although the
possibility that SRG3 mediates the interaction between AR
and the chromatin-remodeling complex cannot be ruled out.
A previous study has shown that Notch1, a transcription
factor, downregulates the expression of SRG3 in macrophages
(7). Deletion analysis of the SRG3 promoter in the present
study revealed that the 76-bp region (210 to 135) contains
a sequence element(s) that is essential for the high level of
SRG3 basal expression, activating expression over 100-fold
(Fig. 1F). The downregulation of SRG3 expression during
prostate development may be related to the transcription fac-
tor that interacts with this sequence element. Developmental
downregulation of the expression of this transcription factor
can maintain low levels of SGR3 expression during the course
of prostate differentiation. The identification and characteriza-
tion of the main factor or factors that regulate SRG3 expres-
sion are important subjects and under active investigation.
The present study also demonstrates that androgen upregu-
lates the expression of SRG3 and that SRG3 is a direct target
gene of AR. To the best of our knowledge, this is the first
report that the expression of core components of the SWI/SNF
complex is regulated by signals such as steroid hormones. Be-
sides having a role in the positive feedback regulation of AR
action, the biological significance of SRG3 induction by andro-
gen remains to be elucidated in relation to the SWI/SNF chro-
matin-remodeling complex.
Upon ligand binding, hormone receptors become activated
and recruit coactivators which adopt diverse modes of action,
including direct interaction with basal transcription factors and
covalent modification of histones and other proteins to induce
the expression of target genes (2, 24, 40, 43). Interestingly,
SRG3 increases the protein level of SRC-1 (Fig. 4A to C) as
well as recruiting SRC-1 to enhance AR transactivation. In-
creased protein stability following an interaction between a
transcription factor and its coactivator has been reported. For
example, Jab1 (Jun activation domain-binding protein 1) in-
teracts with HIF-1 (hypoxia-inducible factor 1) and en-
hances HIF-1 stability, resulting in an increase in the HIF-1
protein level (1). In a similar way, hepatitis B virus X protein
and p300 increase the half-life of activating signal cointegrator
2 and sterol regulatory element binding proteins (SREBPs),
respectively (19, 31). Thus, the increase of protein stability by
protein-protein interaction is likely another action mode of
transcription factor/coactivator to enhance gene expression.
Numerous studies have demonstrated the modulation of AR
function by its coregulators. However, the molecular regula-
tory mechanism of prostate development or regeneration by
androgen is as yet unclear. In this study, we demonstrate that
androgen induces the expression of SRG3 and SRG3 in turn
enhances the transcriptional activity of AR, which provides a
positive feedback regulatory mechanism for AR transactiva-
tion. Furthermore, SRG3 upregulates the protein level of
SRC-1, with which SRG3 cooperates to enhance AR transac-
tivation, providing another regulatory mechanism for AR
transactivation by SRG3. These multiple positive regulatory
mechanisms of AR transactivation by SRG3 may be important
for the rapid proliferation of cells during prostate development
and regeneration, during which the SRG3 expression level is
high.
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